vs
Side-by-side financial comparison of CASEYS GENERAL STORES INC (CASY) and TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA). Click either name above to swap in a different company.
TEVA PHARMACEUTICAL INDUSTRIES LTD is the larger business by last-quarter revenue ($4.7B vs $4.5B, roughly 1.0× CASEYS GENERAL STORES INC). TEVA PHARMACEUTICAL INDUSTRIES LTD runs the higher net margin — 10.2% vs 4.6%, a 5.6% gap on every dollar of revenue. On growth, CASEYS GENERAL STORES INC posted the faster year-over-year revenue change (14.2% vs 11.4%). TEVA PHARMACEUTICAL INDUSTRIES LTD produced more free cash flow last quarter ($1.0B vs $176.0M). Over the past eight quarters, CASEYS GENERAL STORES INC's revenue compounded faster (16.3% CAGR vs 11.1%).
Casey's Retail Company is a chain of convenience stores in the Midwestern and Southern United States. The company is headquartered in Ankeny, Iowa, a suburb of Des Moines. As of October 1, 2023, Casey's had 2,500 stores in 16 states. Following 7-Eleven's purchase of Speedway, Casey's is the third-largest convenience store chain in the United States and the largest that is wholly American-owned. It is one of two Iowa-based Fortune 500 companies. Casey's is famous for their pizza, including a b...
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
CASY vs TEVA — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.5B | $4.7B |
| Net Profit | $206.3M | $481.0M |
| Gross Margin | — | 56.4% |
| Operating Margin | 6.1% | 6.4% |
| Net Margin | 4.6% | 10.2% |
| Revenue YoY | 14.2% | 11.4% |
| Net Profit YoY | 14.0% | 321.7% |
| EPS (diluted) | $5.53 | $0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.5B | $4.7B | ||
| Q3 25 | $4.6B | $4.5B | ||
| Q2 25 | $4.0B | $4.2B | ||
| Q1 25 | $3.9B | $3.9B | ||
| Q4 24 | $3.9B | $4.2B | ||
| Q3 24 | $4.1B | $4.3B | ||
| Q2 24 | $3.6B | $4.2B | ||
| Q1 24 | $3.3B | $3.8B |
| Q4 25 | $206.3M | $481.0M | ||
| Q3 25 | $215.4M | $433.0M | ||
| Q2 25 | $98.3M | $282.0M | ||
| Q1 25 | $87.1M | $214.0M | ||
| Q4 24 | $180.9M | $-217.0M | ||
| Q3 24 | $180.2M | $-437.0M | ||
| Q2 24 | $87.0M | $-846.0M | ||
| Q1 24 | $86.9M | $-139.0M |
| Q4 25 | — | 56.4% | ||
| Q3 25 | — | 51.4% | ||
| Q2 25 | — | 50.3% | ||
| Q1 25 | — | 48.2% | ||
| Q4 24 | — | 50.2% | ||
| Q3 24 | — | 49.6% | ||
| Q2 24 | — | 48.6% | ||
| Q1 24 | — | 46.4% |
| Q4 25 | 6.1% | 6.4% | ||
| Q3 25 | 6.1% | 19.7% | ||
| Q2 25 | — | 10.9% | ||
| Q1 25 | 2.8% | 13.3% | ||
| Q4 24 | 6.1% | -0.7% | ||
| Q3 24 | 5.8% | -1.2% | ||
| Q2 24 | — | -0.1% | ||
| Q1 24 | 3.4% | -5.7% |
| Q4 25 | 4.6% | 10.2% | ||
| Q3 25 | 4.7% | 9.7% | ||
| Q2 25 | 2.5% | 6.8% | ||
| Q1 25 | 2.2% | 5.5% | ||
| Q4 24 | 4.6% | -5.1% | ||
| Q3 24 | 4.4% | -10.1% | ||
| Q2 24 | 2.4% | -20.3% | ||
| Q1 24 | 2.6% | -3.6% |
| Q4 25 | $5.53 | $0.42 | ||
| Q3 25 | $5.77 | $0.37 | ||
| Q2 25 | $2.63 | $0.24 | ||
| Q1 25 | $2.33 | $0.18 | ||
| Q4 24 | $4.85 | $-0.19 | ||
| Q3 24 | $4.83 | $-0.39 | ||
| Q2 24 | $2.34 | $-0.75 | ||
| Q1 24 | $2.33 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $492.0M | $3.6B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.8B | $7.9B |
| Total Assets | $8.6B | $40.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $492.0M | $3.6B | ||
| Q3 25 | $458.1M | $2.2B | ||
| Q2 25 | $326.7M | $2.2B | ||
| Q1 25 | $394.8M | $1.7B | ||
| Q4 24 | $351.7M | $3.3B | ||
| Q3 24 | $305.0M | $3.3B | ||
| Q2 24 | $206.5M | $2.3B | ||
| Q1 24 | $177.9M | $3.0B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $2.4B | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $1.6B | — | ||
| Q1 24 | — | — |
| Q4 25 | $3.8B | $7.9B | ||
| Q3 25 | $3.6B | $7.3B | ||
| Q2 25 | $3.5B | $6.8B | ||
| Q1 25 | $3.4B | $6.3B | ||
| Q4 24 | $3.3B | $5.4B | ||
| Q3 24 | $3.2B | $6.1B | ||
| Q2 24 | $3.0B | $6.4B | ||
| Q1 24 | $2.9B | $7.3B |
| Q4 25 | $8.6B | $40.7B | ||
| Q3 25 | $8.4B | $39.9B | ||
| Q2 25 | $8.2B | $40.1B | ||
| Q1 25 | $8.2B | $38.4B | ||
| Q4 24 | $7.7B | $39.3B | ||
| Q3 24 | $6.5B | $41.8B | ||
| Q2 24 | $6.3B | $41.3B | ||
| Q1 24 | $6.2B | $42.8B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.69× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.52× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $347.1M | $1.2B |
| Free Cash FlowOCF − Capex | $176.0M | $1.0B |
| FCF MarginFCF / Revenue | 3.9% | 21.6% |
| Capex IntensityCapex / Revenue | 3.8% | 3.0% |
| Cash ConversionOCF / Net Profit | 1.68× | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | $682.2M | $1.1B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $347.1M | $1.2B | ||
| Q3 25 | $372.4M | $369.0M | ||
| Q2 25 | $333.9M | $227.0M | ||
| Q1 25 | $204.9M | $-105.0M | ||
| Q4 24 | $270.7M | $575.0M | ||
| Q3 24 | $281.4M | $693.0M | ||
| Q2 24 | $288.4M | $103.0M | ||
| Q1 24 | $122.8M | $-124.0M |
| Q4 25 | $176.0M | $1.0B | ||
| Q3 25 | $262.4M | $233.0M | ||
| Q2 25 | $153.1M | $131.0M | ||
| Q1 25 | $90.7M | $-232.0M | ||
| Q4 24 | $160.0M | $446.0M | ||
| Q3 24 | $180.8M | $545.0M | ||
| Q2 24 | $92.1M | $6.0M | ||
| Q1 24 | $-27.0M | $-248.0M |
| Q4 25 | 3.9% | 21.6% | ||
| Q3 25 | 5.7% | 5.2% | ||
| Q2 25 | 3.8% | 3.1% | ||
| Q1 25 | 2.3% | -6.0% | ||
| Q4 24 | 4.1% | 10.5% | ||
| Q3 24 | 4.4% | 12.6% | ||
| Q2 24 | 2.6% | 0.1% | ||
| Q1 24 | -0.8% | -6.5% |
| Q4 25 | 3.8% | 3.0% | ||
| Q3 25 | 2.4% | 3.0% | ||
| Q2 25 | 4.5% | 2.3% | ||
| Q1 25 | 2.9% | 3.3% | ||
| Q4 24 | 2.8% | 3.1% | ||
| Q3 24 | 2.5% | 3.4% | ||
| Q2 24 | 5.5% | 2.3% | ||
| Q1 24 | 4.5% | 3.2% |
| Q4 25 | 1.68× | 2.41× | ||
| Q3 25 | 1.73× | 0.85× | ||
| Q2 25 | 3.40× | 0.80× | ||
| Q1 25 | 2.35× | -0.49× | ||
| Q4 24 | 1.50× | — | ||
| Q3 24 | 1.56× | — | ||
| Q2 24 | 3.31× | — | ||
| Q1 24 | 1.41× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CASY
Segment breakdown not available.
TEVA
| Other | $2.0B | 42% |
| Generics Medicians Including Otc And Biosimilars | $672.0M | 14% |
| Other Products | $608.0M | 13% |
| License | $529.0M | 11% |
| Distribution Service | $366.0M | 8% |
| Other Activities | $227.0M | 5% |
| Ajovy | $106.0M | 2% |
| COPAXONE | $77.0M | 2% |
| Respiratory Product | $65.0M | 1% |
| Uzedy | $55.0M | 1% |
| Bendeka And Treanda | $36.0M | 1% |
